Astrana Health, Inc. (AMEH) News & Corporate Actions | Announcements, Board Meetings, Splits, Bonuses, Rights Issues

{
  "main_header": {
    "sid": 1150435,
    "name": "Astrana Health, Inc.",
    "stock_name": "Astrana Health, Inc.",
    "full_name": "Astrana Health, Inc.",
    "name_url": "stocks-analysis/astrana-health-inc",
    "exchange": 210,
    "exchangecode": "NAS",
    "country_id": 2,
    "currency": "USD",
    "cmp": "22.79",
    "chg": -0.03,
    "chgp": "-0.13%",
    "dir": -1,
    "prev_price": "22.82",
    "mcapval": "1,654.34",
    "mcap": "Small Cap",
    "scripcode": "",
    "symbol": "",
    "ind_name": "Miscellaneous",
    "ind_code": 3370,
    "indexname": "S&P 500",
    "isin": "US03763A2078",
    "curr_date": "Dec 04",
    "curr_time": "",
    "bse_nse_vol": "518.86 k",
    "exc_status": "Active",
    "traded_date": "Dec 04, 2025",
    "traded_date_str": "2025 12 04",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/astrana-health-inc-1150435-210&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Astrana Health Stock Hits Day Low of $25.54 Amid Price Pressure",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astrana-health-stock-hits-day-low-of-2554-amid-price-pressure-3686555",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/11/AstranaHealthIn_priceRelatedfactors_3686555.png",
        "date": "2025-11-10 17:51:06",
        "description": "Astrana Health, Inc. faced significant stock volatility on November 7, 2025, with a notable decline. Over the past year, the company has underperformed the market, experiencing a substantial drop. Financial metrics show mixed results, including a high return on equity but declining net profit and a low debt-to-equity ratio."
      },
      {
        "title": "Astrana Health, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astrana-health-inc-technical-trend-shifts-from-mildly-bullish-to-bullish-amid-stock-price-increase-3648926",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AstranaHealthIn_technicaldot_3648926.png",
        "date": "2025-10-27 15:32:37",
        "description": "Astrana Health, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock, priced at $33.30, has shown significant volatility over the past year, with a high of $60.99 and a low of $21.20. Technical indicators present a mixed outlook, reflecting ongoing recovery efforts."
      },
      {
        "title": "Is Astrana Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astrana-health-inc-overvalued-or-undervalued-3637959",
        "imagepath": "",
        "date": "2025-10-21 12:12:27",
        "description": "As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 36, which is substantially higher than peers like Premier, Inc. at 11.29 and Select Medical Holdings Corp. at 7.26. Additionally, the EV to EBITDA ratio stands at 14.41, further suggesting that the company's valuation is not justified by its earnings potential.\n\nComparing Astrana Health's performance to the S&P 500, the stock has shown a year-to-date return of 1.52%, significantly lagging behind the index's 13.30% return, and a one-year return of -47.84% compared to the S&P 500's 14.08%. This underperformance reinforces the notion that Astrana Health, Inc. is overvalued in the current market environment...."
      },
      {
        "title": "Astrana Health, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/astrana-healths-valuation-grade-changes-from-expensive-to-very-expensive-amid-market-volatility-3640489",
        "imagepath": "https://i.marketsmojo.com/newsimg/2025/10/AstranaHealthIn_valuationdot_3640489.png",
        "date": "2025-10-20 15:29:23",
        "description": "Astrana Health, Inc. has recently adjusted its valuation, with its stock price at $32.01. The company has faced a notable decline in stock performance over the past year, contrasting with broader market gains. Key financial metrics indicate a higher valuation compared to peers, reflecting differing market perceptions."
      },
      {
        "title": "Is Astrana Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astrana-health-inc-overvalued-or-undervalued-3634832",
        "imagepath": "",
        "date": "2025-10-20 12:29:40",
        "description": "As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears to be overvalued based on its P/E ratio of 36, which is substantially higher than peers like Premier, Inc. at 11.29 and Select Medical Holdings Corp. at 7.26. Additionally, the EV to EBITDA ratio of 14.41 further supports this assessment, as it is elevated compared to the industry standards.\n\nThe company's return metrics also reflect its struggles, particularly with a one-year return of -47.84%, contrasting sharply with the S&P 500's gain of 14.08% during the same period. This underperformance, combined with the very expensive valuation grade, suggests that Astrana Health, Inc. is currently overvalued in the market...."
      },
      {
        "title": "Is Astrana Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astrana-health-inc-overvalued-or-undervalued-3632366",
        "imagepath": "",
        "date": "2025-10-19 12:06:58",
        "description": "As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its current pricing relative to its fundamentals. The company appears to be overvalued based on key metrics, including a P/E ratio of 36, an EV to EBIT of 19.76, and a Price to Book Value of 1.90. In comparison, peers like Premier, Inc. and Select Medical Holdings Corp. show much lower P/E ratios of 11.29 and 7.26, respectively, highlighting the disparity in valuation.\n\nDespite a recent strong performance with a 1-week return of 9.96% compared to the S&P 500's 1.70%, the longer-term outlook is concerning, as the stock has declined 47.84% over the past year while the S&P 500 gained 14.08%. This stark contrast reinforces the notion that Astrana Health, Inc. is currently overvalued in the market...."
      },
      {
        "title": "Is Astrana Health, Inc. technically bullish or bearish?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astrana-health-inc-technically-bullish-or-bearish-3546945",
        "imagepath": "",
        "date": "2025-09-20 19:43:31",
        "description": "As of 8 August 2025, the technical trend for Astrana Health, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals across time frames. The Bollinger Bands also show a mildly bullish stance on the weekly chart but are bearish on the monthly. Daily moving averages are mildly bearish, and the KST is bullish weekly but bearish monthly. Overall, the Dow Theory indicates a mildly bearish trend on the weekly basis with no trend monthly. \n\nIn terms of performance, Astrana Health has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -5.52% versus the S&P 500's 12.22%, and a one-year return of -47.88% compared to 17.14% for the index. This suggests a weak technical stance overall, with bearish tendencies prevailing despite some mildly bullish indicators on shorter time frames...."
      },
      {
        "title": "Is Astrana Health, Inc. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-astrana-health-inc-overvalued-or-undervalued-3543414",
        "imagepath": "",
        "date": "2025-09-20 18:18:42",
        "description": "As of 7 July 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its current valuation. The company appears to be overvalued, with a P/E ratio of 36, which is considerably higher than its peers, such as Premier, Inc. at 11.29 and Select Medical Holdings Corp. at 7.26. Additionally, its EV to EBITDA ratio stands at 14.41, further highlighting the elevated valuation compared to industry standards.\n\nIn terms of financial performance, Astrana Health, Inc. has a ROCE of 8.80% and a ROE of 5.30%, which do not justify its high valuation metrics. The stock has underperformed against the S&P 500 across multiple periods, with a YTD return of -5.52% compared to the index's 12.22%, and a staggering 1-year return of -47.88% versus 17.14% for the S&P 500. This underperformance reinforces the notion that the stock is overvalued in the cu..."
      }
    ],
    "total": 13,
    "sid": "1150435",
    "stock_news_url": "https://www.marketsmojo.com/news/astrana-health-inc-1150435"
  },
  "announcements": "",
  "corporate_actions": {
    "msg": "No corporate action Found"
  }
}

News and Views

Astrana Health Stock Hits Day Low of $25.54 Amid Price Pressure

2025-11-10 17:51:06

Astrana Health, Inc. faced significant stock volatility on November 7, 2025, with a notable decline. Over the past year, the company has underperformed the market, experiencing a substantial drop. Financial metrics show mixed results, including a high return on equity but declining net profit and a low debt-to-equity ratio.

Astrana Health, Inc. Experiences Evaluation Revision Amidst Market Dynamics and Performance Indicators

2025-10-27 15:32:37

Astrana Health, Inc. has recently revised its evaluation amid fluctuating market conditions. The stock, priced at $33.30, has shown significant volatility over the past year, with a high of $60.99 and a low of $21.20. Technical indicators present a mixed outlook, reflecting ongoing recovery efforts.

Is Astrana Health, Inc. overvalued or undervalued?

2025-10-21 12:12:27

As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears to be overvalued based on its current metrics, particularly with a P/E ratio of 36, which is substantially higher than peers like Premier, Inc. at 11.29 and Select Medical Holdings Corp. at 7.26. Additionally, the EV to EBITDA ratio stands at 14.41, further suggesting that the company's valuation is not justified by its earnings potential. Comparing Astrana Health's performance to the S&P 500, the stock has shown a year-to-date return of 1.52%, significantly lagging behind the index's 13.30% return, and a one-year return of -47.84% compared to the S&P 500's 14.08%. This underperformance reinforces the notion that Astrana Health, Inc. is overvalued in the current market environment....

Astrana Health, Inc. Experiences Revision in Its Stock Evaluation Amid Market Challenges

2025-10-20 15:29:23

Astrana Health, Inc. has recently adjusted its valuation, with its stock price at $32.01. The company has faced a notable decline in stock performance over the past year, contrasting with broader market gains. Key financial metrics indicate a higher valuation compared to peers, reflecting differing market perceptions.

Is Astrana Health, Inc. overvalued or undervalued?

2025-10-20 12:29:40

As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant increase in perceived overvaluation. The company appears to be overvalued based on its P/E ratio of 36, which is substantially higher than peers like Premier, Inc. at 11.29 and Select Medical Holdings Corp. at 7.26. Additionally, the EV to EBITDA ratio of 14.41 further supports this assessment, as it is elevated compared to the industry standards. The company's return metrics also reflect its struggles, particularly with a one-year return of -47.84%, contrasting sharply with the S&P 500's gain of 14.08% during the same period. This underperformance, combined with the very expensive valuation grade, suggests that Astrana Health, Inc. is currently overvalued in the market....

Is Astrana Health, Inc. overvalued or undervalued?

2025-10-19 12:06:58

As of 17 October 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its current pricing relative to its fundamentals. The company appears to be overvalued based on key metrics, including a P/E ratio of 36, an EV to EBIT of 19.76, and a Price to Book Value of 1.90. In comparison, peers like Premier, Inc. and Select Medical Holdings Corp. show much lower P/E ratios of 11.29 and 7.26, respectively, highlighting the disparity in valuation. Despite a recent strong performance with a 1-week return of 9.96% compared to the S&P 500's 1.70%, the longer-term outlook is concerning, as the stock has declined 47.84% over the past year while the S&P 500 gained 14.08%. This stark contrast reinforces the notion that Astrana Health, Inc. is currently overvalued in the market....

Is Astrana Health, Inc. technically bullish or bearish?

2025-09-20 19:43:31

As of 8 August 2025, the technical trend for Astrana Health, Inc. has changed from bearish to mildly bearish. The weekly MACD is mildly bullish, while the monthly MACD is bearish, indicating mixed signals across time frames. The Bollinger Bands also show a mildly bullish stance on the weekly chart but are bearish on the monthly. Daily moving averages are mildly bearish, and the KST is bullish weekly but bearish monthly. Overall, the Dow Theory indicates a mildly bearish trend on the weekly basis with no trend monthly. In terms of performance, Astrana Health has underperformed compared to the S&P 500 across multiple periods, with a year-to-date return of -5.52% versus the S&P 500's 12.22%, and a one-year return of -47.88% compared to 17.14% for the index. This suggests a weak technical stance overall, with bearish tendencies prevailing despite some mildly bullish indicators on shorter time frames....

Is Astrana Health, Inc. overvalued or undervalued?

2025-09-20 18:18:42

As of 7 July 2025, the valuation grade for Astrana Health, Inc. has moved from expensive to very expensive, indicating a significant concern regarding its current valuation. The company appears to be overvalued, with a P/E ratio of 36, which is considerably higher than its peers, such as Premier, Inc. at 11.29 and Select Medical Holdings Corp. at 7.26. Additionally, its EV to EBITDA ratio stands at 14.41, further highlighting the elevated valuation compared to industry standards. In terms of financial performance, Astrana Health, Inc. has a ROCE of 8.80% and a ROE of 5.30%, which do not justify its high valuation metrics. The stock has underperformed against the S&P 500 across multiple periods, with a YTD return of -5.52% compared to the index's 12.22%, and a staggering 1-year return of -47.88% versus 17.14% for the S&P 500. This underperformance reinforces the notion that the stock is overvalued in the cu...

View All News